Andrei R. Shustov

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project”.

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Blood(2021)10.1182/blood.2020010387

N/A

3.4DataRank · unranked

126 citations

Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won-Seog Kim +14 more

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

The Lancet Haematology(2021)10.1016/s2352-3026(21)00170-8

N/A

1.6DataRank · unranked

59 citations

Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren +15 more

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Blood Advances(2022)10.1182/bloodadvances.2020003971

N/A

1.1DataRank · unranked

40 citations

Steven M. Horwitz, Ranjana H. Advani, Jacob Haaber Christensen, Eva Domingo‐Doménech, Giuseppe Rossi +19 more

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Blood Cancer Journal(2025)10.1038/s41408-025-01329-2

N/A

0.282DataRank · unranked

5 citations

Barbara Pro, Tim Illidge, Steven M. Horwitz, Lorenz Truemper, Swaminathan P. Iyer +22 more

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma

Blood Advances(2025)10.1182/bloodadvances.2024014263

N/A

0.113DataRank · unranked

1 citations

Parastoo B. Dahi, Farhad Khimani, Andrei R. Shustov, Mazyar Shadman, Jia Ruan +19 more

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7561

N/A

0DataRank · unranked

1 citations

Jonathan R. Fromm, Min Fang, Brian G. Till, Mazyar Shadman, Andrew J. Cowan +11 more

Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses

Blood Advances(2024)10.1182/bloodadvances.2023012461

N/A

0DataRank · unranked

15 citations

Shashidhar Ravishankar, Elshafa H. Ahmed, César Camilo Carías Alvarado, Juan C. Barrios-Menéndez, Oscar Silva +24 more